94.66 +0.01 (0.01%)
After hours: 7:49PM EDT
|Bid||93.95 x 800|
|Ask||94.66 x 1000|
|Day's range||91.98 - 94.67|
|52-week range||72.13 - 122.15|
|Beta (5Y monthly)||0.68|
|PE ratio (TTM)||26.74|
|Earnings date||25 Aug 2020|
|Forward dividend & yield||2.32 (2.50%)|
|Ex-dividend date||25 Jun 2020|
|1y target est||110.17|
The Zacks Analyst Blog Highlights: Alphabet, Merck, Medtronic, Netflix and Anheuser-Busch InBev
Top Stock Reports for Alphabet, Merck & Medtronic
Shares of medical device makers Becton Dickinson (NYSE: BDX), Boston Scientific (NYSE: BSX), and Medtronic (NYSE: MDT) fell by double-digit percentages in the first six months of 2020, according to data provided by S&P Global Market Intelligence. BD's shares slid 12%, Medtronic's were down 19.2%, and Boston Scientific's tumbled 22.4% during the six-month period, trailing the S&P 500, which was only down a modest 4%. All three companies are diversified manufacturers of hundreds of different pieces of medical equipment and devices, both high- and low-tech.
Medtronic's (MDT) FDA and CE Mark-approved LINQ II ICM enables physicians to optimize device settings via remote programming, without requiring patients' in-office visits.
Medtronic plc (NYSE:MDT) and Tandem Diabetes Care, Inc. (NASDAQ:TNDM) today announced that they have entered into a non-exclusive patent cross-license agreement for certain technologies in the field of diabetes. Cross-licensing each other’s patent portfolios enables both companies to focus on helping people with diabetes through innovation of future products and services, while avoiding the distraction of potential legal disagreements.
Medtronic's (MDT) MiniMed Mio Advance infusion set, is aimed at providing optimal user experience to insulin pump-using diabetic patients.
The big jump came after Bloomberg reported that medical device giant Medtronic (NYSE: MDT) made an offer to acquire Intersect. Intersect's revenue fell in the first quarter from the prior-year period. As a result, Intersect lost more than half of its valuation earlier this year.
Next Generation ICM Offers Remote Programming with Improved Longevity and Enhanced Accuracy DUBLIN, July 07, 2020 -- Medtronic plc (NYSE:MDT), the global leader in medical.
Medtronic plc (MDT), the global leader in medical technology, today introduced the MiniMed™ Mio™ Advance infusion set to all Medtronic insulin pump customers in the United States. The MiniMed Mio Advance infusion set is the newest addition to the MiniMed™ portfolio of infusion sets and gives people using insulin pumps an optimal user experience with fewer steps1. The MiniMed Mio Advance infusion set is inserted in only four steps — individuals simply peel, pinch, place, and press to insert the infusion set.
Medtronic plc (MDT), the global leader in medical technology, today announced the start of a prospective, observational, global, multi-center, real-world, post-market study to evaluate the safety and effectiveness of the Valiant Navion™ Thoracic Stent Graft System in the treatment of thoracic aortic dissection. The first patient procedure in the DISSECT-N study was performed at Northwell Health in New York, New York by Derek Brinster, M.D., director of Aortic Surgery.
There's been lots of volatility on the markets this year since the outbreak of COVID-19, a lot of which has come as a result of more retail investors getting involved in the markets. Robinhood's attracted investors by offering commission-free trades, making it easier to place small bets on stocks. Here's why you should generally avoid stocks that are popular on Robinhood.
Medtronic's (MDT) first-of-its-kind Percept PC DBS system with the next-generation BrainSense technology clears FDA hurdle, paving the way for data-driven neurostimulation treatment.
Medtronic plc (MDT), the global leader in medical technology, today reported new data from the Global SYMPLICITY Registry (GSR), which showed that renal denervation (RDN) with the Medtronic Symplicity™ Renal Denervation System significantly reduced blood pressure (BP) in uncontrolled hypertension patients out to three years independent of anti-hypertension medication burden. The data were presented virtually as part of the PCR e-Course 2020.
Medtronic plc (MDT), the global leader in medical technology, today announces it received Food and Drug Administration (FDA) approval for the Percept™ PC Deep Brain Stimulation (DBS) system. BrainSense™ technology makes Percept the first and only DBS neurostimulation system with the ability to chronically capture and record brain signals while delivering therapy to patients with neurologic disorders associated with Parkinson’s disease, essential tremor, dystonia, epilepsy or obsessive-compulsive disorder (OCD).
Medtronic plc (MDT), the global leader in medical technology, today announced CE (Conformité Européenne) mark and European launch of the Evolut™ Transcatheter Aortic Valve Implantation (TAVI) system for patients with severe native aortic stenosis who are at a low risk of surgical mortality. The low-risk patient population is the final surgical risk category to be approved for this minimally invasive alternative to open-heart surgical valve replacement (SAVR) and includes patients who may be younger1 and more active than higher-risk patients.
Medtronic (MDT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Medtronic (MDT) enters into a partnership with Foxconn with an aim of providing 10,000 PB560 ventilators in the United States over the next year amid the pandemic-led surge in demand for the same.
Medtronic plc (MDT) and Foxconn Industrial Internet, a business group within Foxconn Technology Group (Foxconn), announced today that Foxconn has successfully completed Medtronic’s regulatory and quality requirements necessary to begin manufacturing Medtronic Puritan Bennett™ 560 (PB560) ventilators for Medtronic in the United States. Medtronic and Foxconn are currently ramping up plans to produce 10,000 PB560 ventilators over the next year at Foxconn’s Wisconn Valley Science and Technology Park in Mount Pleasant, Wis. The ventilators will be marketed and sold by Medtronic.
Medtronic plc (MDT), the global leader in medical technology, today announced the first-ever results from the ABRE clinical study assessing the safety and effectiveness of the investigational Abre™ venous self-expanding stent system in subjects with iliofemoral venous outflow obstruction. “Deep venous lesions are uniquely challenging and require a stent that is strong, flexible, and durable, while also being able to maintain blood flow,” said Stephen Black, M.D., consultant vascular surgeon, Guy's and St. Thomas' Hospital, London and European principal investigator for the ABRE Study.